Amgen to buy Onyx Pharmaceuticals; Onyx declines; ups offer, finalized at $9.2bn
Executive Summary
Amgen Inc. has offered to buy cancer therapeutics developer Onyx Pharmaceuticals Inc. for $120 per share (a 41% premium), for a total of $8.7bn.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice